Overview

Treatment of Cancer with Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2030-08-01

Target enrollment:

Participant gender:

Summary

This phase 1 clinical trial aims to evaluate the safety, tolerability and feasibility of combination treatment of High Intensity Focused Ultrasound Histotripsy (HIFU-HT) and immune checkpoint inhibitors (ICI) in adult patients with metastatic or unresectable cancer that have progressive disease after regular treatment. Patients will undergo one single session of HIFU-HT during treatment with ipilimumab and nivolumab. Safety, tolerability and feasibility endpoints will be studied as well as radiologic, immunologic and clinical response.

Phase:

PHASE1

Details

Lead Sponsor:

UMC Utrecht

Treatments:

Immune Checkpoint Inhibitors